Cell targeting conjugates
A technology of cell targeting and conjugates, which is applied in drug combinations, medical preparations of non-active ingredients, anti-tumor drugs, etc., and can solve problems such as toxicity and affecting the immunological characteristics of antibodies
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0072] Materials and methods
[0073] general material
[0074] The cell lines used were breast cancer cell lines MDA-MB231, JIMT, BT-474 and SKBR3, ovarian cancer cell line SKOV and gastric cancer cell line NCI-N87. JIMT-1 was obtained from DSMZ Germany on March 19, 2012, after cytogenetic testing and used within 6 months of resuscitation. NCI-N87 was obtained at ATCC UK on 29 February 2012, following cytogenetic testing and used within 6 months of resuscitation. SKBR3 was obtained from Dr. T. Oude Munnink (Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands), MDA-MB-231 from Roche, and SK-OV-3 from Department of Medical Oncology, VU University Medical Center Amsterdam. All cell lines were examined for primary growth characteristics (morphology and growth rate) and HER2 expression. MDA-MB231 is a cell line with low HER2 expression; SKBR3, BT-474, SKOV-3, and NCI-N87 overexpress HER2; and JIMT-1 is developed from tumor cells of...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


